以色列拉阿纳纳，2025年7月15日 — Polyrizon Ltd.（纳斯达克代码：PLRZ）作为一家专注于鼻内水凝胶技术的生物技术公司，在解决合规问题后成功保留了纳斯达克资本市场的上市地位。纳斯达克听证小组于2025年6月26日批准了公司的上诉请求，条件是Polyrizon必须在2025年10月17日前满足最低出价规则的要求。公司承诺在未来的融资活动中避免使用复杂或稀释性的金融工具，并正实施一套内部控制框架以确保符合纳斯达克标准。首席执行官Tomer Izraeli对提升股东价值和强化企业业务地位表达了乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.